Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren’s syndrome

Table 2 Observed and expected numbers of unique R and S mutations per time point and overall in the large clone of Sjögren’s syndrome subject 2

Time	N	CDR R obs	CDR S obs	FWR R obs	FWR S obs	CDR R exp	CDR S exp	FWR R exp	FWR S exp
All	55	6	24	46	47	27.18	9.59	62.36	23.86
Week 0	1	1	1	6	9	3.76	1.33	8.59	3.32
Week 8	17	5	18	30	36	19.67	6.94	45.12	17.27
Week 14	7	1	11	17	22	11.27	3.98	25.86	9.89
Week 26	10	1	14	22	25	13.70	4.84	31.43	12.03
Week 36	6	2	5	18	22	10.39	3.67	23.83	9.12
Week 52	14	1	5	10	22	8.40	2.96	19.27	7.37

Shown are the observed (obs) and expected (exp) numbers of replacement (R) and silent (S) mutations within each unique clonally related variant at each time point for members of the big clone in Sjögren’s syndrome subject 2. Both the complementarity-determining region (CDR) and the framework region (FWR) exhibit significant negative selection at all time points and overall (P <0.05 by the focused selection test; see Methods). N, number.

ISSN: 1478-6362